Daijiworld Media Network - Bhubaneswar

Bhubaneswar, Jul 20: In a major medical breakthrough, the Regional Medical Research Centre (RMRC) in Bhubaneswar, under the Indian Council of Medical Research (ICMR), has developed a cutting-edge malaria vaccine designed to prevent plasmodium falciparum infection and limit its transmission in communities.

Named AdFalciVax, the recombinant chimeric multi-stage vaccine has shown promising pre-clinical results. Validation of the technology was carried out in collaboration with ICMR’s National Institute of Malaria Research (NIMR), other ICMR institutes, and the National Institute of Immunology (NII), New Delhi.

The ICMR has now invited Expression of Interest (EoI) from eligible companies and manufacturers for the Transfer of Technology to commercially produce the vaccine.

ICMR-RMRCBB will extend expert guidance and full technical support during all production phases to expedite the development and roll-out of the vaccine. Additionally, ICMR scientists will assist in protocol planning, data analysis, safety and efficacy evaluation, and potential product improvements in coordination with the selected manufacturing partner.